EA Pharma/Kissei Prepping to File Ulcerative Colitis Drug on Positive Japan PIII

EA Pharma and Kissei Pharmaceutical said on January 13 that their α4 integrin inhibitor carotegrast methyl hit the primary endpoint in a Japan PIII study for the treatment of ulcerative colitis (UC). With these results, the pair is now preparing...read more